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AIMS: Neoadjuvant chemotherapy followed by surgery is the standard of care for patients with gastro-oesophageal adenocarcinoma.
Previously, we validated the utility of the tumour regression grade (TRG) as a histopathological marker of tumour downstaging in
patients receiving platinum-based neoadjuvant chemotherapy. In this study we profiled key DNA repair and damage signalling factors
and correlated them with clinicopathological outcomes, including TRG response.
METHODS AND RESULTS: Formalin-fixed human gastro-oesophageal cancers were constructed into tissue microarrays (TMAs). The first
set consisted of 142 gastric/gastro-oesophageal cancer cases not exposed to neoadjuvant chemotherapy and the second set
consisted of 103 gastric/gastro-oesophageal cancer cases exposed to preoperative platinum-based chemotherapy. Expressions of
ERCC1, XPF, FANCD2, APE1 and p53 were investigated using immunohistochemistry.
In patients who received neoadjuvant chemotherapy, favourable TRG response (TRG 1, 2 or 3) was associated with improvement in
disease-specific survival (P¼0.038). ERCC1 nuclear expression correlated with lack of histopathological response (TRG 4 or 5) to
neoadjuvant chemotherapy (P¼0.006) and was associated with poor disease-specific (P¼0.020) and overall survival (P¼0.040).
CONCLUSIONS: We provide evidence that tumour regression and ERCC1 nuclear protein expression evaluated by
immunohistochemistry are promising predictive markers in gastro-oesophageal cancer patients receiving neoadjuvant platinum-
based chemotherapy.
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Neoadjuvant platinum-based chemotherapy followed by surgery
is the standard of care for patients with gastro-oesophageal
adenocarcinoma (Medical Research Council Oesophageal Cancer
Working Group, 2002; Cunningham et al, 2006). We recently
reported the utility of tumour regression grade (TRG) analyses as a
marker of histopathological response and tumour downstaging in
tumours receiving neoadjuvant chemotherapy (Fareed et al, 2009).
TRG was defined as per Mandard’s criteria (Mandard et al, 1994).
In brief, TRG1 (complete regression) showed absence of residual
cancer and fibrosis extending through the different layers of the
oesophageal wall; TRG2 was characterised by the presence of rare
residual cancer cells scattered through the fibrosis; TRG3 was
characterised by an increase in the number of residual cancer cells
but fibrosis predominated; TRG4 showed residual cancer out-
growing fibrosis; and TRG5 was characterised by the absence of
regressive changes (Mandard et al, 1994). In the neoadjuvant
chemotherapy (CS) group (n¼84), 46.7% of gastric/gastro-
oesophageal junction adenocarcinomas, and 45.5% of lower third
oesophageal adenocarcinomas, had TRG 1, 2 or 3 compared with
13.7% in the primary surgery group (n¼124; Po0.001 and
P¼0.006, respectively). In CS group, responders (TRG 1, 2 or 3)
showed significant tumour downstaging (early ypT-stage disease
(P¼0.002)). In gastric cancers specifically, additional associations
were observed with negative nodal disease (P¼0.044) and absence
of vascular invasion (P¼0.027; Fareed et al, 2009).
The response rate to platinum-based chemotherapy in gastro-
oesophageal tumours is approximately 40% (Medical Research
Council Oesophageal Cancer Working Group, 2002; Cunningham
et al, 2006, 2008). Although platinum therapy has been a major
advance in improving patient outcomes, the development of
treatment-related toxicity and the emergence of resistance (both
intrinsic and acquired) limit the effectiveness of platinating agents
in solid tumours (Siddik, 2003; Rabik and Dolan, 2007). Platinum
interacts with DNA to form predominantly intra-strand crosslink
DNA adducts that trigger a series of intracellular events that
ultimately result in cell death (Siddik, 2003; Zorbas and Keppler,
2005; Cepeda et al, 2007). DNA intra-strand crosslinks are
processed and repaired by the nucleotide excision repair (NER)
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spathway in mammalian cells (Madhusudan and Hickson, 2005;
Madhusudan and Middleton, 2005; Reardon and Sancar, 2005;
Gillet and Scharer, 2006; Gossage and Madhusudan, 2007). Of the
several factors involved, ERCC1-XPF heterodimer has been shown
to have an important role in NER. Inactivation of NER results
in platinum hypersensitivity in preclinical studies (Gossage and
Madhusudan, 2007). In addition to NER, the Fanconi anaemia (FA)
pathway has recently emerged as being critically involved in the
regulation of DNA crosslink repair in mammalian cells (Levitus
et al, 2006; Wang, 2007). Although the exact molecular mechanism
is not completely known, it is clear that in response to crosslinkers,
a complex consisting of at least eight FA proteins (A, B, C, E, F,
G, L and M) monoubiquinates FANCD2, which is subsequently
targeted to the chromatin in which it interacts with FANCD1
(also known as BRCA2) to facilitate DNA repair that may require
the components of the nucleotide excision repair, homologous
recombination and non-homologous end joining machinery
(Mirchandani and D’Andrea, 2006; Wang, 2007). Disruption of
the FA/BRCA pathway by germline mutations in FA genes results
in crosslinker hypersensitivity (D’Andrea and Grompe, 2003;
Chen et al, 2005; van der Heijden et al, 2005; Bartz et al, 2006;
Wang et al, 2006; Zhang et al, 2006). Human apurinic/apyrimidinic
endonuclease (APE1) is a multifunctional protein that has an
essential role in DNA base excision repair involved in the repair
of base damage, including oxidative base damages induced by
platinating agents (Demple and Sung, 2005). Overexpression of
APE1 results in relative resistance to platinating agents in
preclinical models (Wang et al, 2009; Zhang et al, 2009). The
p53 tumour suppressor protein has an essential role in DNA
damage signal recognition and response. p53 is a transcription
factor that binds to specific sites in the regulatory regions of p53-
responsive genes, leading to cellular events such as growth arrest
(perhaps to allow for DNA repair), or where there is extensive
DNA damage to initiate apoptosis. p53 expression is common in
gastro-oesophageal cancer and may influence response to chemo-
therapy (Kamoshida et al, 2007).
In this study we profiled key DNA repair and damage signalling
factors involved in processing platinum-induced DNA lesions
(ERCC1, XPF, APE1, FANCD2 and p53) and correlated them
with clinicopathological outcomes in gastro-oesophageal cancer
patients treated with platinum-based chemotherapy.
MATERIALS AND METHODS
Study design and setting
Investigation of the expression of DNA repair and DNA damage
signalling factors in gastro-oesophageal cancers was carried out
on two tissue microarray (TMA) sets. The first set consisted of
142 gastric/gastro-oesophageal cancer cases not exposed to
neoadjuvant chemotherapy. With recent incorporation of
neoadjuvant chemotherapy as a standard treatment option for
operable gastro-oesophageal tumours (Cunningham et al, 2006),
we also established a second TMA of 103 gastric/gastro-
oesophageal cancer cases exposed to preoperative platinum-based
chemotherapy. Tissue was obtained from patients treated at
Nottingham University Hospitals (NUH) between 2001 and 2008.
Survival was calculated from the date of diagnosis until 13 January
2009, when any remaining survivors were censored. During the
study period, patients in the neoadjuvant arm with adenocarci-
nomas were treated with either neoadjuvant ECF (epirubicin
(50mgm
–2), cisplatin (60mgm
–2) and continuous infusional
5-FU (200mgm
–2 per day)) or ECX (epirubicin (50mgm
–2),
cisplatin (60mgm
–2) and capecetabine (625mgm
–2 p.o. b.d
continuously)) chemotherapy up to three cycles before surgery.
Patients with squamous cell carcinoma were treated with CF
(cisplatin (80mgm
–2) and infusional 5-FU (1000mgm
–2daily for
4 days)) (Allum et al, 2009) chemotherapy up to two cycles before
surgery. The conduct of this study was approved by the ethics
committee of Nottingham University Hospitals.
Construction of TMA
Tissue microarrays were constructed as described previously
(Kononen et al, 1998). In short, area-specialised histopathologists
identified and marked formalin-fixed paraffin-embedded tissue
blocks containing tumour tissue on haematoxylin and eosin-
stained slides. The marked areas in these donor paraffin blocks
were used to construct the TMA. Triplicate tissue cores with a
diameter of 0.6mm were taken from the marked areas and arrayed
into a recipient paraffin block using a tissue puncher/arrayer
(Beecher Instruments, Silver Spring, MD, USA) as previously
described (Kononen et al, 1998). Sections of the tissue array block
(5mm) were cut and placed on Fisherbrand Colorfrost/Plus
microscope slides (Fisher Scientific, Pittsburgh, PA, USA) for
immunohistochemical staining.
Immunohistochemistry (IHC)
A standard streptavidin-biotin-peroxidase complex method was
used. Negative controls were obtained by omitting the primary
antibody in each case. The tissue slides were deparaffinised with
xylene and then rehydrated through five decreasing concentrations
of alcohol (100, 90, 70, 50 and 30%) for 2min each. Endogenous
peroxidise activity was blocked by incubation in a 1% hydrogen
peroxide/methanol buffer. Antigen retrieval was carried out by
microwave treatment of the slides in sodium citrate buffer (pH 6.0)
for 10min. The slides were rinsed in phosphate buffer solution
(PBS) and incubated with blocking serum diluted in PBS to block
nonspecific staining. For ERCC1 analysis the slides were incubated
for 1h with the primary anti-ERCC1 antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) in a dilution of 1:50.
For XPF analysis the slides were incubated for 1h with the primary
anti-XPF antibody (Abcam Plc, Cambridge, UK) in a dilution of
1:50. For FANCD2 analysis the slides were incubated for 1h with
the primary anti-FANCD2 antibody (Novus Biologicals Inc.,
Littleton, CO, USA) in a dilution of 1:200. For APE1 analysis the
slides were incubated for 1h with the primary anti-APE1 antibody
(Novus Biologicals) in a dilution of 1:500. For p53 analysis the
slides were incubated for 1h with the primary anti-p53 antibody
(Vector Labs, Burlingame, CA, USA) in a dilution of 1:50. All
primary antibody dilutions were made in PBS. After washing with
PBS, sections were incubated with the secondary antibody (Vector
Labs) for 30min followed by the avidin-biotin complex for a
further 30min. 3-30 Diaminobenzidine tetrahydochloride was used
as a chromogen. All sections were counterstained with Gill’s
haematoxylin.
Evaluation of immune staining
The tumour cores were evaluated by specialist pathologist and
oncologist together who were blinded to the clinico-pathological
characteristics of patients. A consensus score was agreed for each
core by the investigators.
Whole field inspection of the core was included in the assess-
ment, and intensities of staining were grouped as follows: 0¼no
staining, 1¼weak staining, 2¼moderate staining and 3¼strong
staining. Nuclear staining was assessed separately for each core.
Strong, moderate or weak nuclear staining was considered as
positive staining. For p53 staining analysis, the level of protein
accumulation was scored as 0 (no detectable immunostain), 1 (few
nuclei), 2 (up to 10% nuclei), 3 (10–50% nuclei) and 4 (450%
nuclei) based on previously published literature (Shiao et al, 1998).
Only stained malignant cells were included in the evaluation of
staining. Not all cores within the TMA were suitable for IHC
analyses because of small technical problems such as some cores
DNA repair in gastro-oesophageal cancers
KR Fareed et al
1601
British Journal of Cancer (2010) 102(11), 1600–1607 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
swere missing or lacked tumours. Only adenocarcinomas were
included in the immunohistochemical analyses.
Statistical analysis
Statistical analysis of data was performed using SPSS version 15.0
for Windows (SPSS Inc., Chicago, IL, USA). Univariate analysis of
associations was determined using Pearson’s w
2 test. Survival rates
were calculated from the time of diagnosis until the end of the
follow-up period and Kaplan–Meier curves were plotted. The
statistical significance of differences between survival rates was
determined using the log-rank test. Survival was censored if the
patient was still alive. The P-values of o0.05 were identified as
statistically significant.
RESULTS
Patient demographics
There were two groups of patients: those who received at least one
cycle of neoadjuvant chemotherapy (neoadjuvant group) and those
who underwent primary surgery (primary group; Table 1). There
were 103 patients in the neoadjuvant group, with a median age of
63 years and 81% were males. In this group, T3 tumours were the
majority, making 62% of cases. The primary group had 142 cases,
with a median age of 74 years, in which 74% were males and 53%
had T3 tumours. In addition, 78% had received all the planned
three cycles of neoadjuvant ECF/ECX chemotherapy (adenocarci-
nomas) and 96.4% had received all the planned two cycles of
neoadjuvant CF chemotherapy (squamous cell carcinomas) in the
neoadjuvant group. Of the patients who received all three cycles of
ECF/ECX chemotherapy, 42% went on to receive the remaining
three cycles of ECF/ECX chemotherapy. There was no significant
difference between the primary surgery group and perioperative
chemotherapy group (gastric/gastro-oesophageal junction) with
regard to T stage (T2 (37 vs 33.3%) and T3 (48.4 vs 40%)) and
N stage (N0 (27 vs 37.8%) and 4N0 (73 vs 62.2%)). Only adeno-
carcinomas were included in the immunohistochemical and
survival analyses in this study.
TRG and survival
Our previous study reported the utility of TRG analysis as a
histopathological marker of response to neoadjuvant chemo-
therapy and tumour downstaging (Fareed et al, 2009). However, at
the time of publication of that study long term follow-up clinical
data were not available. In this study we show that patients who
received neoadjuvant chemotherapy and achieved favourable
tumour regression (TRG 1, 2 or 3) showed significantly better
disease-specific survival compared with non-responders (Figure 1).
The median disease-specific survival in TRG 1–3 (responders) was
51.7 vs 27.6 months in TRG 4 and 5 (non-responders; P¼0.038).
The median overall survival in TRG 1–3 (responders) was 36.1 vs
27.6 months in TRG4-5 (non-responders; P¼0.136).
In the primary surgery group in which patients did not receive
neoadjuvant chemotherapy, we found that patients whose tumours
had spontaneous regression (TRG 1, 2 or 3) had a favourable mean
overall survival of 61.8 months compared with 36.5 months in TRG
4and 5 group (P¼0.003; Figure 2). Similar trend was also observed
for disease-specific survival, although it did not reach statistical
significance (mean survival 68.6 months (TRG 1–3) compared
with 53.9 months (TRG 4 and 5); P¼0.87; Figure 2).
Immunohistochemical analyses and clinicopathological
correlations
ERCC1 A total of 57 cores were suitable for analyses in the
neoadjuvant group. Out of 57, 28 (49.2%) were ERCC1 positive and
29 (50.8%) were ERCC1 negative in the nucleus (Figure 3 and
Table 2). Tumours that were ERCC1 positive showed no histo-
pathological response to chemotherapy as evidenced by a TRG
score of 4 or 5. This was statistically significant (P¼0.006;
Table 2). There were no significant associations between ERCC1
expression and other variables such as late T stage (T3 or T4),
nodal involvement, vascular or perineural involvement. The
median disease-specific survival in nuclear-positive ERCC1
patients was 20.9 vs 39.1 months in nuclear-negative patients
(P¼0.020). The median overall survival in nuclear-positive ERCC1
patients was 20.9 vs 36.1 months in nuclear-negative patients
(P¼0.040; Figure 4).
In the primary surgery group, 94 cores were suitable for
analyses. ERCC1 positivity was frequently observed (69 out of 94
(73.4%)) but this did not correlate with any clinicopathological
variables. ERCC1 nuclear expression was not associated with
disease-specific (P¼0.956) or overall survival (P¼0.905).
Table 1 Patients’ demographics
Number (%)
(neoadjuvant
chemotherapy group)
Number (%)
(primary
surgery group)
Total number of patients 103 142
Median age 63 years 74 years
Sex
Male 83 (81%) 105 (73.9%)
Female 20 (19%) 37 (26%)
T stage
T1 4 (3.8%) 14 (9.8%)
T2 24 (23.6) 48 (33.8%)
T3 64 (62%) 75 (52.8%)
T4 9 (8.6%) 5 (3.5%)
TX 2 (2%)
N stage
N0 29 (28%) 33 (23.2%)
XN1 74 (72%) 109 (76.8%)
M stage
M0 103 (100%) 140 (98.5%)
M1 — 2 (1.4%)
Tumour type
Adenocarcinoma 88 (85.4%) 142 (100%)
Squamous cell carcinoma 13 (12.6%) —
Adenosquamous 2 (1.9%) —
Site of tumour
Gastric 20 (19.4%) 142 (100%)
GOJ 47 (45.6%) —
Lower third of oesophagus 36 (35%) —
Surgery
Total gastrectomy 22 70
Partial gastrectomy 5 52
Oesophagectomy/
oesophago- gastrectomy
76 20
TRG response after
chemotherapy
1, 2 and 3 43 (41.7%) —
4 and 5 60 (58.3%) —
Survival status
Alive 47 (46%) 54 (38%)
Dead 56 (54%) 87 (62%)
Abbreviations: GOJ¼gastro-oesophageal junction; TRG¼tumour regression grade.
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sXPF A total of 61 cores were suitable for analyses in the
neoadjuvant group and 102 cores in primary surgery group.
Nuclear XPF expression was frequently observed (neoadjuvant
group 55 out of 61 (90.2%) and primary surgery group 101 out
of 102 (99%)). There was no correlation with TRG and other
clinicopathological variables.
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TRG4,TRG5 (non-
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(responders)
TRG4,TRG5 (non-
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Figure 1 Kaplan–Meier curves representing the relationship between tumour regression grade (TRG) and disease-specific and overall survival in months
from time of diagnosis in patients having received neoadjuvant chemotherapy.
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Figure 2 Kaplan–Meier curves representing the relationship between tumour regression grade (TRG) and disease-specific and overall survival in months
from time of diagnosis in patients who received surgery only.
P53 APE1 ERCC1
Figure 3 Microphotographs of ERCC1 (strongly positive), APE1 (strongly positive) and p53 (450% nuclei staining) immunohistochemical staining
showing nuclear expression in tissue microarray cores (magnification  100).
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sFANCD2 A total of 57 cores were suitable for analyses in the
neoadjuvant group and 91 cores in the primary surgery group.
Nuclear XPF expression was observed (neoadjuvant group 37 out
of 57 (65%) and primary surgery group 59 out of 91 (65%)). There
was no correlation with TRG and other clinicopathological
variables.
APE1 A total of 46 cores were suitable for analyses in the
neoadjuvant group and 93 cores in primary surgery group. Nuclear
APE1 expression was observed (neoadjuvant group, 28 out of 46
(60.9%) and primary surgery group, 63 out of 93 (67.7%); Figure 3
and Table 2). There was no correlation with TRG, T stage, N stage,
vascular or perineural invasion. Interestingly, in the neoadjuvant
group, median disease-specific survival in nuclear-positive APE1
patients was 17.5 vs 37.5 months in nuclear-negative patients.
This was statistically significant (P¼0.005; Figure 5).
p53 A total of 66 cores were suitable for analyses in the
neoadjuvant group and 122 cores in the primary surgery group.
Nuclear p53 expression was frequently observed (neoadjuvant
group, 35 out of 66 (53%) and primary surgery group, 39 out
of 122 (32%); Figure 3 and Table 2). In the primary surgery group
p53 positivity significantly correlated with nodal involvement
(P¼0.016) and perineural invasion (0.023). The mean disease-
specific survival in patients expressing 410% nuclei p53 staining
was 41.5 vs 67.2 months in those expressing o10% nuclei staining
(P¼0.028; Figure 6). The median overall survival in patients
expressing 410% nuclei p53 staining was 26.7 vs 53.2 months in
those expressing o10% nuclei staining (Po0.001). No significant
association was observed in the neoadjuvant chemotherapy group
(Figure 6).
DISCUSSION
The role of multimodality therapy in improving patient outcomes is
generally accepted but remains controversial in gastro-oesophageal
cancers. Current evidence suggests that preoperative treatment
does not adversely affect surgical outcomes (Cunningham et al,
2006). However, only those patients who respond to preoperative
therapy with tolerable toxicity will potentially benefit from this
approach. The risk of delaying surgery in those patients who do
not respond to chemotherapy may negatively influence clinical
outcome. Moreover, the role of adjuvant chemotherapy in patients
Table 2 Nuclear expression and correlation with lack of tumour
response (TRG 4 or 5) in the neoadjuvant chemotherapy group
Positive
(%)
Negative
(%)
Lack of tumour response
to chemotherapy
ERCC1 28/57 (49.1%) 29/57 (50.8%) 0.006
a
XPF 55/61 (90.2%) 6/61 (9.8%) 0.498
FANCD2 37/57 (65%) 20/57 (35%) 1.0
APE1 28/46 (60.9%) 18/46 (39.1%) 0.295
TP53 35/66 (53%) 31/66 (47%) 0.706
Abbreviation: TRG¼tumour regression grade.
aPositive nuclear staining significantly
correlated with lack of tumour response (i.e., TRG 4 or 5).
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Figure 4 Kaplan–Meier curves representing the relationship between ERCC1 nuclear expression and disease-specific and overall survival in months from
the time of diagnosis in the neoadjuvant group (n¼57 patients).
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Figure 5 Kaplan–Meier curves representing the relationship between
APE1 expression and disease-specific survival in the neoadjuvant group
(n¼46 patients).
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swho have received neoadjuvant chemotherapy is uncertain,
particularly in patients who show no evidence of tumour response
to preoperative chemotherapy. Reliable evaluation of tumour
response in the surgical resection specimens would be helpful in
planning postoperative chemotherapy. In addition, predictive
markers of response would be invaluable in individualising patient
treatment as it would enable discrimination of those patients likely
to respond to combination therapy from those likely to be non-
responsive. In particular, for those patients who had achieved little
or no response to preoperative chemotherapy, the use of alternative
forms of adjuvant therapy could be considered to improve
outcomes. Until the recent incorporation of neoadjuvant chemo-
therapy as a standard treatment option for operable gastro-
oesophageal tumours (Cunningham et al, 2006), fit patients
routinely received surgery in our centre. Therefore, the first set
consisted of 142 gastric cancer cases not exposed to neoadjuvant
chemotherapy. Biomarker investigations in this set may provide
prognostic information in patients. With the incorporation of
neoadjuvant chemotherapy since 2006, we also established a second
TMA of 103 gastric/gastro-oesophageal cancer cases exposed to
preoperative platinum-based chemotherapy. Biomarker investiga-
tions in this set may provide predictive information in patients.
In the previous study we provided the first evidence that TRG
analysis correlate with tumour downstaging in gastro-oesophageal
tumours (Fareed et al, 2009). In this study we have shown that
lack of histopathological response to preoperative chemotherapy
is associated with poor disease-specific survival (P¼0.038). Our
study suggests the potential need for alternative chemotherapy
strategies in adjuvant setting in non-responders. However, larger
studies would be required to confirm our findings and to allow
design of clinical trials to address this clinical problem. In our
previous study we reported on spontaneous regression of tumours
not exposed to chemotherapy (Fareed et al, 2009). In this study we
present the first evidence to suggest that spontaneous regression in
tumour may be associated with better overall survival. The most
extensive TRG in patients who had not received chemotherapy was
in patients with predominantly mucosal disease, who had marked
submucosal and muscularis propria fibrosis. In the absence of
neoadjuvant chemotherapy, this could represent partial regression
in tumours. Whether host immune factors such as lymphocytic
infiltration could contribute to spontaneous regression is currently
unknown and is an area of ongoing investigation. An alternative
explanation is that this represents nonspecific scarring in an ulcer
base due to a coexistent or preceding benign peptic ulcer with
partial or complete mucosal tumour ‘healing’ overlying it (Fareed
et al, 2009).
We then conducted an investigation of potential biomarkers
that may have the ability to predict favourable/unfavourable
TRG response ((TRG 1, 2 or 3) or (TRG 4 or 5) respectively). We
focussed on key DNA repair and damage signalling factors, as the
antitumour activity of platinum-based chemotherapy is largely
dependent on the DNA repair capacity of cancer cells. In our study,
78% had received all the planned three cycles of neoadjuvant
ECF/ECX chemotherapy for adenocarcinomas, and it is unlikely
that this may have influenced the immunohistochemistry marker
expression. We show that nuclear expression of ERCC1 is signi-
ficantly associated with resistance to chemotherapy (TRG 4 or 5),
implying that ERCC1 is a promising predictive marker. Moreover,
we have also shown that nuclear ERCC1 expression correlates with
poor disease-specific (P¼0.005) and overall survival (P¼0.005) in
operable gastro-oesophageal tumours. However, in tumours not
exposed to neoadjuvant chemotherapy, ERCC1 expression did not
correlate with survival, implying that ERCC1 is likely to have
predictive significance rather than prognostic significance in these
tumours.
Elevated ERCC1 mRNA expression has previously been shown
to predict resistance to chemotherapy in gastro-oesopahgeal
tumours (Metzger et al, 1998; Warnecke-Eberz et al, 2004; Joshi
et al, 2005). The ability of ERCC1 mRNA levels in predicting
response has also been shown in lung (Lord et al, 2002; Simon
et al, 2005), colorectal (Shirota et al, 2001), ovarian (Dabholkar
et al, 1992, 1994) and bladder cancer (Bellmunt et al, 2007).
A recent study used immunohistochemistry to examine ERCC1
expression in the primary tumours of 64 patients with advanced
gastric cancer treated with 5-FU/oxaliplatin chemotherapy.
Patients without ERCC1 expression were more likely to respond
to chemotherapy, and this was also associated with significantly
longer median overall survival (Kwon et al, 2007). Our results are
consistent with the above findings. In addition, we have provided
the first evidence of ERCC1 protein expression in early-stage
gastro-oesophageal tumours using immunohistochemistry. More-
over, our results are consistent with a recent study in lung cancer
patients. The IALT Biology Study used immunohistochemical
analysis to determine the expression of the ERCC1 protein in the
operative lung cancer specimens. Among 761 tumours, ERCC1
expression was positive in 335 (44%) and negative in 426 (56%).
A benefit from cisplatin-based adjuvant chemotherapy was
associated with the absence of ERCC1 (Olaussen et al, 2006).
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Figure 6 Kaplan–Meier curves representing the relationship between p53 nuclear expression and disease-specific survival in the primary surgery group.
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sNuclear expression of XPF, FANCD2, p53 and APE1 did not
correlate with TRG response. However, nuclear expression of APE1
in the neoadjuvant group correlated with worse disease-specific
(P¼0.020) and overall survival (P¼0.040). No significant
correlations were observed in tumours not exposed to neoadjuvant
chemotherapy. We have recently shown a similar correlation in
ovarian cancer in which nuclear expression was associated with
worse survival. In addition, APE1 expression was associated with
a trend towards platinum resistance in patients (P¼0.07;
Al-Attar et al, 2010). Nuclear p53 correlated with disease-specific
(P¼0.028) and overall survival (Po0.001) in the primary surgery
group but no significant associations were observed in the
neoadjuvant group. This is in contrast to a study by Kamoshida
et al (2007), who showed that p53 expression was correlated with
resistance to chemotherapy in gastric cancer patients.
Our study is limited by the retrospective design and small
numbers of tumours. We have provided evidence that TRG
correlates with survival and ERCC1 nuclear expression is
associated with resistance to chemotherapy as assessed by TRG
and is also associated with poor disease-specific and overall
survival. Larger studies are needed to validate this observation that
is likely to have important clinical implications for patients
receiving neoadjuvant chemotherapy for gastro-oesophageal
cancer.
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